Biologics in ocular inflammatory diseases – Experience from a tertiary referral eye care center in South India
Authors:
Open Access
- 10 September 2024
- journal article
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 73 (2) , 267-272
Abstract
Purpose: To analyze the utility of biologics in noninfectious uveitis and other ocular inflammatory diseases in a South Indian patient population. Methods: This was a retrospective observational study conducted at the uveitis and ocular inflammatory diseases clinic of a tertiary eye care hospital in South India between 2016 and 2023. Results: Records of 76 patients on biologics were retrieved from our databases. The mean age was 34.84 ± 17.383 years. In 75% of patients, the duration of follow-up was 52.75 months. Overall, anterior nongranulomatous uveitis was the most common anatomic type of uveitis (34.21%). HLA B27-associated uveitis was the most common etiology (34.21%) in whom biologics were used. Patients P = 0.001). Adverse effects were seen in 14 patients (18.42%). The success rate of biologics was low in the parsplanitis group <18 years (33.3%), Blau-associated uveitis (50%), and idiopathic uveitis (30%). Conclusion: In this study, we have analyzed the results of biologics in different anatomic types of ocular inflammation and etiologies. The success rate of biologics was low in parsplanitis, idiopathic uveitis, and Blau-associated uveitis and higher in other etiologies.Keywords
This publication has 19 references indexed in Scilit:
- Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis RegistryOphthalmology and Therapy, 2024
- Branch retinal vein occlusion in a case of recalcitrant diffuse anterior scleritis treated with tofacitinibJournal of Ophthalmic Inflammation and Infection, 2023
- Peripheral Ulcerative Keratitis in a Young Lady with Systemic Lupus Erythematosus Post Rituximab Infusion-A Case ReportOcular Immunology and Inflammation, 2022
- Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature reviewClinical Rheumatology, 2021
- Biologic Drugs for the Treatment of Noninfectious UveitisAsia-Pacific Journal of Ophthalmology, 2021
- The current status of biological treatment for uveitisExpert Review of Clinical Immunology, 2020
- Juvenile idiopathic arthritis-associated uveitisClinical Immunology, 2020
- JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitisClinical Rheumatology, 2020
- A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious UveitisOphthalmology and Therapy, 2017
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005